In addition, patients responding to ICIs have high pre-treatment levels of CD4+ and CD8+ T cells in the tumor parenchyma in proximity to the tumor cells, a patient profile defined as an immune-inflamed phenotype (“hot” tumor) [2,4,5]. Here, CD4 is linked to neoplasm.